Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27570571 | 0.72 | AR (0.47) | MEN1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL13284002 | 0.66 | CYP19A1 (0.56) | MEN1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL13510366 | 0.66 | HTR2B (0.55) | MEN1RAB9AKMT2AALDH1A1MAPT | |
| SCHEMBL3193066 | 0.66 | CYP19A1 (0.53) | RAB9AKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL27486008 | 0.66 | CCNC (0.33) | — | |
| SCHEMBL13510369 | 0.64 | CYP19A1 (0.41) | MEN1RAB9AKMT2AKDM4EMAPT | |
| SCHEMBL7003561 | 0.63 | KDM4E (0.49) | MEN1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL1702959 | 0.63 | — | — | |
| SCHEMBL1928655 | 0.62 | SMN1; SMN2 (0.45) | MEN1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL28453477 | 0.61 | LCK (0.32) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006033795-A2 | SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | TYMP, DPYD, TYMS | MEN1 2653/4885RAB9A 3615/4885KMT2A 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.